ArticleMolecular vision2013
Association of Pro12Ala polymorphism in peroxisome proliferator activated receptor gamma with proliferative diabetic retinopathy.
Article in Molecular vision, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Association betweenAging · 2021Pooled it
- PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Long Noncoding RNAs and Mitochondrial Homeostasis in the Development of Diabetic Retinopathy.Frontiers in endocrinology · 2022Review
- The role of the PPARG (Pro12Ala) common genetic variant on type 2 diabetes mellitus risk.Journal of diabetes and metabolic disorders · 2021Article
- Association of Peroxisome Proliferator-Activated Receptors (PPARs) with Diabetic Retinopathy in Human and Animal Models: Analysis of the Literature and Genome Browsers.PPAR research · 2020Review
- Peroxisome proliferator-activated receptor-γ polymorphism (rs1801282) is associated with obesity in Egyptian patients with coronary artery disease and type 2 diabetes mellitus.Journal, genetic engineering & biotechnology · 2017Article
- ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.The American journal of clinical nutrition · 2017Review
- A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression.Scientific reports · 2016Article
- Candidate gene studies of diabetic retinopathy in human.Molecular biology reports · 2016Review
- Update on genetics and diabetic retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
- Interaction between peroxisome proliferator- activated receptor gamma polymorphism and overweight on diabetic retinopathy in a Chinese case-control study.International journal of clinical and experimental medicine · 2015Article
- Role of ACE and PAI-1 Polymorphisms in the Development and Progression of Diabetic Retinopathy.PloS one · 2015Article
- GRK5 intronic (CA)n polymorphisms associated with type 2 diabetes in Chinese Hainan Island.PloS one · 2014Article
- ASSOCIATION BETWEEN PRO12ALa POLYMORPHISM OF PPARγ2 GENE AND CORONARY ARTERY DISEASE IN IRANIAN POPULATION WITH TYPE TWO DIABETES MELLITUS.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe association of non-synonymous substitution polymorphism rs1801282 (c.34C>G, p.Pro12Ala) in exon 4 of the peroxisome proliferator activated receptor gamma gene with diabetic retinopathy (DR) has been reported inconsistently. Therefore, the purpose of the present study was to understand the population-specific role of the Pro12Ala polymorphism in DR susceptibility in Pakistani subjects.
methodsA total of 180 subjects with DR, 193 subjects with type 2 diabetes mellitus (T2DM) with no diabetic retinopathy, and 200 healthy normoglycemic non-retinopathic Pakistani individuals were genotyped for the rs1801282 (c.34C>G) polymorphism using polymerase chain reaction-restriction fragment length polymorphism.
resultsWe found the individuals with T2DM carrying 12Ala were at a reduced risk of developing DR (odds ratio [OR]=0.53; 95% confidence interval [CI]=0.33-0.87). Upon stratified analysis regarding disease severity, we observed this protective effect was confined to proliferative DR (OR=0.4; 95% CI=0.2-0.8) with non-significant effects on the susceptibility of non-proliferative DR (OR=0.67; 95% CI=0.37-1.19).
conclusionsWe report a protective role of the 12Ala polymorphism against proliferative DR in individuals with T2DM in Pakistan.
Indexed as
Identifiers
23559865PMC3611930W2115738015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.